Informed Consent
Item
1. signed and dated informed consent
boolean
C0021430 (UMLS CUI [1])
Non-Small Cell Lung Carcinoma Advanced TNM clinical staging | Nidus Measurable
Item
2. diagnosed with advanced nsclc (phase iiib/iv) through pathology, with measurable nidus(using recist 1.1)
boolean
C0007131 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C3258246 (UMLS CUI [1,3])
C1628997 (UMLS CUI [2,1])
C1513040 (UMLS CUI [2,2])
Systemic Chemotherapy Quantity
Item
3. at least two systematic chemotherapy with upwards of 3-line treatments or cannot suffer
boolean
C1883256 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Tumor tissue sample | Hydrothorax Tissue specimen | EGFR Negative | ALK Negative | EGFR Positive | ALK Positive | Tolerance to drug | Tolerance to drug Absent | Status post Targeted Therapy
Item
4. patients must provide detectable specimen (from tumor tissue or hydrothorax) before participating, who negative in egfr&alk can participate or who positive in egfr&alk, have or have not drug tolerance after the treatment with relative targeted drugs
boolean
C0475358 (UMLS CUI [1])
C0020312 (UMLS CUI [2,1])
C1292533 (UMLS CUI [2,2])
C1414313 (UMLS CUI [3,1])
C1513916 (UMLS CUI [3,2])
C4524838 (UMLS CUI [4])
C4525189 (UMLS CUI [5])
C4290023 (UMLS CUI [6])
C0556444 (UMLS CUI [7])
C0556444 (UMLS CUI [8,1])
C0332197 (UMLS CUI [8,2])
C0231290 (UMLS CUI [9,1])
C2985566 (UMLS CUI [9,2])
ECOG performance status | Life Expectancy
Item
5. ecog ps:0-1,expected survival time: over 3 months
boolean
C1520224 (UMLS CUI [1])
C0023671 (UMLS CUI [2])
Organ function
Item
6. main organs function is normal
boolean
C0678852 (UMLS CUI [1])
Childbearing Potential Contraceptive methods | Intrauterine Devices | Contraceptives, Oral | Female Condoms | Breast Feeding Absent | Serum pregnancy test negative | Urine pregnancy test negative | Gender Contraceptive methods
Item
7. the woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; the man patients who must agree to take contraceptive methods during the research and within another 6 months after it
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0021900 (UMLS CUI [2])
C0009905 (UMLS CUI [3])
C0221829 (UMLS CUI [4])
C0006147 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
C0430061 (UMLS CUI [6])
C0430057 (UMLS CUI [7])
C0079399 (UMLS CUI [8,1])
C0700589 (UMLS CUI [8,2])
anlotinib
Item
1. have used anlotinib before
boolean
C4519250 (UMLS CUI [1])
Small cell carcinoma of lung | Carcinoma, Small Cell | Cancer Other
Item
2. small cell lung cancer (including small cell cancer and other kinds of cancer mixed with non-small cell cancer)
boolean
C0149925 (UMLS CUI [1])
C0262584 (UMLS CUI [2])
C1707251 (UMLS CUI [3])
EGFR mutation Positive | ALK mutation Positive | Tyrosine kinase inhibitor Absent
Item
3. examined as positive in egfr&alk mutation detection and never take the treatment of tkis
boolean
C3266992 (UMLS CUI [1,1])
C1514241 (UMLS CUI [1,2])
C2825843 (UMLS CUI [2,1])
C1514241 (UMLS CUI [2,2])
C1268567 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
Squamous cell carcinoma of lung | Pleural cavity | Non-Small Cell Lung Carcinoma | Hemoptysis
Item
4. central lung squamous carcinoma along with cavum, or non-small cell lung cancer along with hemoptysis (>50ml/day)
boolean
C0149782 (UMLS CUI [1])
C0178802 (UMLS CUI [2])
C0007131 (UMLS CUI [3])
C0019079 (UMLS CUI [4])
Cancer Other
Item
5. other kinds of malignancies within 5 years or for now
boolean
C1707251 (UMLS CUI [1])
Cancer treatment Systemic Planned | Cytotoxic therapy | Signal Transduction Inhibitor | Immunotherapy | Mitomycin | Extended-Field Radiation Therapy | Therapeutic radiology procedure Radiation Field Limited
Item
6. plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the medicine-taking period of this research, including cytotoxic therapy, signal transduction inhibitor, and immunotherapy (or who use mitomycin c within 6 weeks before taking the treatment with experimental drug); the patients who have already taken extended field radiotherapy (ef-rt) within 4 weeks before grouping or limited field radiotherapy with proposed assessment of nidus within 2 weeks before grouping
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,3])
C0677881 (UMLS CUI [2])
C1519313 (UMLS CUI [3])
C0021083 (UMLS CUI [4])
C0002475 (UMLS CUI [5])
C3826855 (UMLS CUI [6])
C1522449 (UMLS CUI [7,1])
C1882536 (UMLS CUI [7,2])
C0439801 (UMLS CUI [7,3])
Toxic reaction Due to Prior Therapy CTCAE Grades | Exception Alopecia
Item
7. have got non remissive toxic reactions derived from previous therapies, which is over level 1 in ctc ae (4.0), alopecia not included
boolean
C0542243 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,3])
C1516728 (UMLS CUI [1,4])
C1705847 (UMLS CUI [2,1])
C0002170 (UMLS CUI [2,2])
Factor Affecting Oral medication | Lacking Able to swallow | Gastrointestinal tract excision | Chronic diarrhea | Ileus chronic
Item
8. with kinds of factors which affect oral medicine (e.g. failing to swallow, gastrointestinal tract getting resected, chronic diarrhea and ileus)
boolean
C1521761 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0175795 (UMLS CUI [1,3])
C0332268 (UMLS CUI [2,1])
C2712086 (UMLS CUI [2,2])
C1293479 (UMLS CUI [3])
C0401151 (UMLS CUI [4])
C1258215 (UMLS CUI [5,1])
C0205191 (UMLS CUI [5,2])
Pleural effusion disorder CTCAE Grades | Ascites | Respiration Disorders
Item
9. pleural effusion or ascites, resulting in respiratory syndrome (≥ctc ae level 2)
boolean
C0032227 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
C0003962 (UMLS CUI [2])
C0035204 (UMLS CUI [3])
Symptoms Metastatic malignant neoplasm to brain Uncontrolled | Symptoms Metastatic malignant neoplasm to brain Untreated
Item
10. symptoms of brain metastases cannot be controlled and treated within less than 2 months
boolean
C1457887 (UMLS CUI [1,1])
C0220650 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
C1457887 (UMLS CUI [2,1])
C0220650 (UMLS CUI [2,2])
C0332155 (UMLS CUI [2,3])
Disease Severe | Disease Uncontrolled
Item
11. get any severe diseases or the ones that cannot be controlled
boolean
C0012634 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0012634 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
Major surgery | Incisional biopsy | Traumatic injury
Item
12. take major surgical treatments, open biopsy, or get overt traumatic injury within 28 days before grouping
boolean
C0679637 (UMLS CUI [1])
C0184922 (UMLS CUI [2])
C3263723 (UMLS CUI [3])
Hemorrhage | Wound, non-healed | Ulcer | Fracture | Hemorrhage and Bleeding Adverse Event CTCAE Grades
Item
13. have any habitus or medical history of hemorrhage, however severe it is; the patients who have non healing wounds, ulcer or fracture after any events with hemorrhage or bleeding (≥ctcae level 3)
boolean
C0019080 (UMLS CUI [1])
C0750433 (UMLS CUI [2])
C0041582 (UMLS CUI [3])
C0016658 (UMLS CUI [4])
C1556642 (UMLS CUI [5,1])
C1516728 (UMLS CUI [5,2])
Arterial thrombosis | Venous Thrombosis | Cerebrovascular accident | Ischemic stroke Temporary | Deep Vein Thrombosis | Pulmonary Embolism
Item
14. get arterial/venous thrombosis within 6 months, such as cerebrovascular accidents (including temporary ischemic stoke), deevenous thrombosis, and pulmonary embolism
boolean
C0151942 (UMLS CUI [1])
C0042487 (UMLS CUI [2])
C0038454 (UMLS CUI [3])
C0948008 (UMLS CUI [4,1])
C0205374 (UMLS CUI [4,2])
C0149871 (UMLS CUI [5])
C0034065 (UMLS CUI [6])
Pharmaceutical Preparations Psychiatric Abuse | Pharmaceutical Preparations Psychiatric Discontinue Unable | Mental disorders
Item
15. ever abuse psychiatric drugs and cannot abstain or who are diagnosed with mental disorder
boolean
C0013227 (UMLS CUI [1,1])
C0205487 (UMLS CUI [1,2])
C0013146 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0205487 (UMLS CUI [2,2])
C1444662 (UMLS CUI [2,3])
C1299582 (UMLS CUI [2,4])
C0004936 (UMLS CUI [3])
Study Subject Participation Status | Antineoplastic Agents
Item
16. have participated in other clinical trials of anti-tumor medicine within 4 weeks
boolean
C2348568 (UMLS CUI [1])
C0003392 (UMLS CUI [2])
Disease High risk Patient safety | Disease Influence Completion of clinical trial
Item
17. diagnosed with disease which will severely endanger the security of patients or influence the completion of this research.
boolean
C0012634 (UMLS CUI [1,1])
C4319571 (UMLS CUI [1,2])
C1113679 (UMLS CUI [1,3])
C0012634 (UMLS CUI [2,1])
C4054723 (UMLS CUI [2,2])
C2732579 (UMLS CUI [2,3])